Navigation Links
Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)
Date:5/18/2008

Study Suggests that Adding Singulair to Advair Offers no Additional

Improvement in Overall Asthma Control

RESEARCH TRIANGLE PARK, N.C. and TORONTO, May 18 /PRNewswire-FirstCall/ -- Patients with both asthma and allergic rhinitis, or seasonal allergies, experience significantly better lung function when treated with Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as compared with Singulair (montelukast sodium). The results of the 660-subject study were presented today at the International Conference of the American Thoracic Society meeting in Toronto.

The study also showed patients treated with Advair plus Singulair saw no measurable improvement compared to patients treated with Advair alone in their asthma symptoms or albuterol use. In another comparison patients using Advair plus the intranasal corticosteroid, fluticasone propionate nasal spray, saw significant improvement in daytime nasal symptoms compared to patients treated with Advair plus Singulair (p<0.001).

"These findings give us a greater understanding of how to treat patients with asthma and seasonal allergies, two diseases that often are seen in tandem," said Rohit Katial, MD, National Jewish Medical Research Center. "By using the right combination of treatments, physicians can help patients gain relief from the symptoms of both diseases."

The study included people age 15 and up who had both persistent asthma and seasonal allergies. Patients received one of four different treatments: Advair Diskus 100/50 twice daily, Singulair 10 mg once daily, Advair 100/50 twice daily with Singulair 10 mg once daily or Advair 100/50 twice daily with fluticasone propionate nasal spray 200 mcg once daily. Those who received Advair alone had significant improvements in their morning peak expiratory flow, a measure of asthma control, as compared with Singulair alone (p<0.001). Secondary endpoints, including symptom-free days and rescue-treat
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
2. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
3. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
4. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
7. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
8. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
9. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
10. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
11. Prism Glasses Expand the View for Patients with Hemianopia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 2American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 3American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 4American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 5American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 6American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 7Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 2Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 3Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 4
(Date:9/17/2014)... The Oliver Law Group P.C. is urging all ... Non-Sterile Other-Sonic Ultrasound Transmission Gel to contact the Firm ... recourse. Other-Sonic ultrasound gel was recalled by the U.S. ... the product was linked to a 2011 outbreak of ... Oak, Michigan . While victims of this outbreak may ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... LA JOLLA, CASeptember 17, 2014Scientists at The Scripps ... based on vancomycin that is powerfully effective against ... , The new vancomycin analog appears to have ... action, against which bacteria probably cannot evolve resistance ... that once introduced will still be in clinical ...
(Date:9/17/2014)... Dallas, TX (PRWEB) September 18, 2014 ... control avian influenza, instead of immunizations. The total number ... which are difficult to control, will result in huge ... poultry with avian influenza vaccines. , Avian influenza vaccines ... China. Some poultry farms in China began to use ...
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
Breaking Medicine News(10 mins):Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3
... , , KIBBUTZ SHAMIR, ... SHMR ) (" Shamir ") expects to issue its second quarter ... a conference call to discuss the results at 11:00 A.M. EDT that ... broadcast live as a listen-only webcast. To listen live, please go to ...
... , , BETHESDA, Md., Aug. 6 ... developing novel, proprietary antibodies for the treatment of cancer, inflammation ... second quarter and six months ended June 30, 2009. , ... Micromet achieved a number of significant milestones illustrating its continued ...
... revised higher based on solid year-to-date performance and, positive ... Aug. 6 /PRNewswire-FirstCall/ - SXC Health Solutions Corp. ("SXC" or the "Company") ... the three- and six-month periods ended June 30, 2009. Financial references are ... Q2 2009 Highlights, ------------------, - ...
... , , WILMINGTON, Mass., Aug. 6 DUSA Pharmaceuticals, ... highlights and second quarter financial results press release will be issued on Tuesday, August ... , , Tuesday, August 11 - 8:30 a.m. E.T. , ... 800.647.4314 , Password - DUSA , , ...
... ... two additional contracts to the RTP, NC-based life sciences company Entegrion, ... safety and availability of blood-derived products for treating combat injuries. ... essential in responding to traumatic injury, especially on the battlefield. ...
... , ... plans provided by GetOnlineQuotes.com offer the best value in the current marketplace. , ... Miami, FL (PRWEB) August ... by law, the AARP Medicare Supplement ( http://www.getonlinequotes.com/aarp-medicare-insurance.html ) rates offered by ...
Cached Medicine News:Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 2Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 4Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 5Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 6Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 7Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 8Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 9Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 10Health News:Micromet, Inc. Reports Second Quarter 2009 Financial Results 11Health News:SXC Health solutions announces record second quarter financial results 2Health News:SXC Health solutions announces record second quarter financial results 3Health News:SXC Health solutions announces record second quarter financial results 4Health News:SXC Health solutions announces record second quarter financial results 5Health News:SXC Health solutions announces record second quarter financial results 6Health News:SXC Health solutions announces record second quarter financial results 7Health News:SXC Health solutions announces record second quarter financial results 8Health News:SXC Health solutions announces record second quarter financial results 9Health News:SXC Health solutions announces record second quarter financial results 10Health News:SXC Health solutions announces record second quarter financial results 11Health News:SXC Health solutions announces record second quarter financial results 12Health News:SXC Health solutions announces record second quarter financial results 13Health News:SXC Health solutions announces record second quarter financial results 14Health News:SXC Health solutions announces record second quarter financial results 15Health News:SXC Health solutions announces record second quarter financial results 16Health News:SXC Health solutions announces record second quarter financial results 17Health News:SXC Health solutions announces record second quarter financial results 18Health News:SXC Health solutions announces record second quarter financial results 19Health News:U.S. Navy Awards Entegrion Contracts for $4 Million for the Development of Critical Blood Products 2Health News:U.S. Navy Awards Entegrion Contracts for $4 Million for the Development of Critical Blood Products 3Health News:GetOnlineQuotes.com to Offer AARP/United Healthcare Medicare Supplement Insurance to Florida Residents 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: